DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant

Transplant International

Volumn 27, Issue 7, 2014, Pages 667-673

  Tagliamacco, Augusto ^a   Cioni, Michela ^b   Comoli, Patrizia ^c   Ramondetta, Miriam ^d   Brambilla, Caterina ^d   Trivelli, Antonella ^b   Magnasco, Alberto ^b   Biticchi, Roberta ^a   Fontana, Iris ^e   Dulbecco, Pietro ^a   Palombo, Domenico ^e   Klersy, Catherine ^c   Ghiggeri, Gian Marco ^b   Ginevri, Fabrizio ^b   Cardillo, Massimo ^d   Nocera, Arcangelo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

Antibody mediated rejection; de novo HLA antibodies; HLA donor specific antibodies; HLA matching; pediatric kidney transplantation

Indexed keywords

ANTIBODY; DONOR SPECIFIC ANTIBODY; HLA DQ ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALPHA CHAIN; ANTIBODY MEDIATED REJECTION; ANTIGEN SPECIFICITY; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HLA SYSTEM; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; DONOR; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA-DQ ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 84902544885     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12316     Document Type: Article

References (28)

1. Terasaki PI,. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
2. El-Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
3. Dunn TB, Noreen H, Gillingham K, et al,. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132.
4. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
5. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al,. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
6. Hidalgo LG, Campbell PM, Sis B, et al,. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
7. Lee PC, Zhu L, Terasaki PI, Everly MJ,. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
8. Mao Q, Terasaki PI, Cai J, et al,. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864.
9. Lachmann N, Terasaki PI, Budde K, et al,. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
10. Kimball PM, Baker MA, Wagner MB, King A,. Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011; 79: 1131.
11. Wiebe C, Gibson IW, Blydt-Hansen TD, et al,. Evolution and clinical pathologic correlations of De Novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 5: 1157.
12. Ginevri F, Nocera A, Comoli P, et al,. Post-transplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody mediated rejection. Am J Transplant 2012; 12: 3355.
13. Willicombe M, Brookes P, Sergeant R, et al,. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172.
14. DeVos JM, Gaber AO, Knight RJ, et al,. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598.
15. Everly MJ, Rebellato LM, Haisch CE, et al,. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410.
16. Pei R, Lee Jh, Shih NJ, Chen M, Terasaki PI,. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 15: 43.
17. Poli F, Cardillo M, Scalamogna M,. Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. Hum Immunol 2009; 70: 631.
18. Cecka JM,. The role of HLA in renal transplantation. Hum Immunol 1997; 56: 6.
19. Susal C, Opelz G,. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269.
20. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
21. Montgomery RA, Hardy MA, Jordan SC, et al,. Consensus opinion from the antibody working group on the diagnosis, reporting and risk assessment for antibody-mediated rejection and desensitisation protocols. Transplantation 2004; 78: 181.
22. Tait BD, Süsal C, Gebel HM, et al,. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19.
23. Deng CT, El-Awar N, Ozawa M, Cai J, Lachmann N, Terasaki PI,. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation 2008; 86: 452.
24. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH,. Indirect allorecognition of donor class I and I1 major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 2001; 12: 2500.
25. Heeger PS,. T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant 2003; 3: 525.
26. Racusen LC, Leffel MS,. C1q-binding antibodies in kidney transplantation. N Engl J Med 2013; 369: 1266.
27. Wiebe C, Pochinco D, Blydt-Hansen TD, et al,. Class II HLA epitope matching-A strategy to minimize donor specific antibody development and improve outcomes. Am J Transplant 2013; 13: 3114.
28. Zachary AA, Montgomery RA, Leffell MS,. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364.